Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
BMC Neurol ; 23(1): 386, 2023 Oct 26.
Artículo en Inglés | MEDLINE | ID: mdl-37884876

RESUMEN

Bickerstaff's brainstem encephalitis is a rare autoimmune disorder that presents with ataxia, ophthalmoplegia, disturbance of consciousness and quadriplegia. A 45-year-old man with a history of ulcerative colitis (UC) taking mesalazine (5-aminosalicylic acid) visited the emergency room presenting with ataxia, ophthalmoplegia and a progressively worsening cognitive impairment. Cerebrospinal fluid analysis showed mild elevation in protein and white blood cell count and increased intracranial pressure. Anti-GQ1b autoantibodies were found positive in the patient's serum and contrast-enhanced brain magnetic resonance imaging showed diffuse leptomeningeal enhancement and pontine lesions. Based on these findings and the patient's clinical course and history, he was diagnosed with Bickerstaff's brainstem encephalitis. Mesalazine was discontinued and high-dose steroid pulse therapy was started, followed by intravenous immunoglobulin, which resulted in gradual improvement of the neurologic symptoms. When an ulcerative colitis patient presents with progressive cognitive impairment, quadriplegia and disturbance of consciousness and gait, Bickerstaff brainstem encephalitis should be considered in the differential diagnosis and prompt immunotherapy may lead to favorable prognosis.


Asunto(s)
Enfermedades Autoinmunes del Sistema Nervioso , Colitis Ulcerosa , Encefalitis , Oftalmoplejía , Masculino , Humanos , Persona de Mediana Edad , Tronco Encefálico/diagnóstico por imagen , Tronco Encefálico/patología , Colitis Ulcerosa/complicaciones , Colitis Ulcerosa/patología , Mesalamina , Encefalitis/complicaciones , Encefalitis/diagnóstico , Cuadriplejía , Ataxia/complicaciones , Gangliósidos
2.
Clin Orthop Surg ; 8(1): 123-6, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26929811

RESUMEN

Snapping hip syndrome is a relatively common problem that can be easily managed with conservative treatment. This syndrome can be divided into external, internal and intra-articular types. Internal snapping hip syndrome is the rarest amongst these and its etiology is not well understood. We report a unique case of osteochondroma arising from the anterior inferior iliac spine (AIIS), which caused the internal snapping hip syndrome with hip pain and restriction of activity. This rare case of snapping hip syndrome from the AIIS was treated surgically and the symptoms completely disappeared after excision of the tumor.


Asunto(s)
Neoplasias Óseas , Articulación de la Cadera , Ilion , Artropatías , Osteocondroma , Adulto , Femenino , Articulación de la Cadera/diagnóstico por imagen , Articulación de la Cadera/fisiopatología , Humanos , Ilion/diagnóstico por imagen , Ilion/fisiopatología , Artropatías/etiología , Artropatías/fisiopatología
3.
Neurochem Res ; 27(3): 215-24, 2002 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11958519

RESUMEN

The present study examined the effect of MAO inhibitors, deprenyl and harmaline, on the membrane permeability transition in brain mitochondria. Deprenyl, harmaline, and antioxidant enzymes (SOD and catalase) attenuated alteration of the swelling, membrane potential, cytochrome c release, and Ca2+ transport in mitochondria treated with dopamine. In contrast, deprenyl and harmaline did not reduce the peroxynitrite-induced change in membrane permeability. Deprenyl and harmaline inhibited the decrease in thioredoxin reductase activity and the thiol oxidation in mitochondria treated with dopamine but did not decrease the effect of peroxynitrite. Deprenyl and harmaline significantly decreased the formation of melanin from dopamine. The results suggest that deprenyl and harmaline may protect brain mitochondria against the toxic action of dopamine oxidation by the maintenance of thioredoxin reductase activity, inhibition of thiol oxidation, and inhibition of dopamine oxidation product formation. In contrast, MAO inhibitors may not defend brain mitochondria against damaging action of peroxynitrite.


Asunto(s)
Encéfalo/fisiología , Dopamina/farmacología , Harmalina/farmacología , Membranas Intracelulares/fisiología , Mitocondrias/fisiología , Dilatación Mitocondrial/fisiología , Ácido Peroxinitroso/farmacología , Selegilina/farmacología , Animales , Peróxido de Hidrógeno/metabolismo , Membranas Intracelulares/efectos de los fármacos , Cinética , Masculino , Mitocondrias/efectos de los fármacos , Dilatación Mitocondrial/efectos de los fármacos , Inhibidores de la Monoaminooxidasa/farmacología , Permeabilidad , Ratas , Ratas Sprague-Dawley , Estereoisomerismo , Reductasa de Tiorredoxina-Disulfuro/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...